Candida Auris, Often Drug-Resistant, Found in 7 States — Physician’s First Watch

Medical News |
May 19, 2017

Candida Auris, Often Drug-Resistant, Found in 7 States

By Amy Orciari Herman

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

As of mid-May 2017, a total of 77 clinical cases of Candida auris in U.S. health care facilities were reported to the CDC, according to a report in MMWR. The agency first warned about the often multidrug-resistant fungus in June 2016.

Of the 77 cases, 53 occurred in New York, 16 in New Jersey, and the rest in Illinois, Indiana, Maryland, Massachusetts, and Oklahoma. All cases were found on cultures during routine patient care. Screening for colonization of close contacts — usually patients on the same ward — revealed an additional 45 patients from whom C. auris was isolated. The fungus was also isolated from patients' mattresses, windowsills, chairs, and countertops.

Testing of the first 35 clinical isolates found that 86% were resistant to fluconazole, and 43% were resistant to amphotericin B. One isolate was resistant to echinocandins.

The authors say the data suggest that the fungus "can spread within health care facilities and that interventions are needed to prevent transmission during this early stage of C. auris emergence."

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.